Vitalant Research Institute, San Francisco, CA, USA.
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Int J Obes (Lond). 2024 Dec;48(12):1711-1719. doi: 10.1038/s41366-024-01603-6. Epub 2024 Aug 12.
Cardiometabolic diseases are risk factors for COVID-19 severity. The extent that cardiometabolic health represents a modifiable factor to mitigate the short- and long-term consequences from SARS-CoV-2 remains unclear. Our objective was to evaluate the associations between intraindividual variability of cardiometabolic health indicators and COVID-19 related hospitalizations and post-COVID conditions (PCC) among a relatively healthy population.
This retrospective, multi-site cohort study was a post-hoc analysis among individuals with cardiometabolic health data collected during routine blood donation visits in 24 US states (2009-2018) and who responded to COVID-19 questionnaires (2021-2023). Intraindividual variability of blood pressure (systolic, diastolic), total circulating cholesterol, and body mass index (BMI) were defined as the coefficient of variation (CV) across all available donation timepoints (ranging from 3 to 74); participants were categorized into CV quartiles. Associations were evaluated by multivariable binomial regressions.
Overall, 3344 participants provided 42,090 donations (median 9 [IQR 5, 17]). The median age was 48 years (38, 56) at the first study donation. 1.2% (N = 40) were hospitalized due to COVID-19 and 15.5% (N = 519) had PCC. Higher BMI variability was associated with greater risk of COVID-19 hospitalization (4th quartile aRR 4.15 [95% CI 1.31, 13.11], p = 0.02; 3rd quartile aRR 3.41 [95% CI 1.09, 10.69], p = 0.04). Participants with higher variability of BMI had greater risk of PCC (4th quartile aRR 1.29 [95% CI 1.02, 1.64]; p = 0.04). Intraindividual variability of blood pressure (systolic, diastolic) and total circulating cholesterol were not associated with COVID-19 hospitalization or PCC risk (all p > 0.05). From causal mediation analysis, the association between the highest quartiles of BMI variability and PCC was not mediated by hospitalization (p > 0.05).
Higher intraindividual variability of BMI was associated with COVID-19 hospitalization and PCC risk. Our findings underscore the need for further elucidating mechanisms that explain these associations and importance for consistent maintenance of body weight.
心血管代谢疾病是 COVID-19 严重程度的危险因素。心血管代谢健康在多大程度上代表了减轻 SARS-CoV-2 短期和长期后果的可改变因素仍不清楚。我们的目的是评估心血管代谢健康指标个体内变异性与相对健康人群中 COVID-19 相关住院和 COVID 后状况(PCC)之间的关联。
这是一项回顾性、多地点队列研究,是在美国 24 个州(2009-2018 年)进行常规献血访问期间收集心血管代谢健康数据的个体中的事后分析,以及对 COVID-19 问卷做出回应的个体(2021-2023 年)。血压(收缩压、舒张压)、总循环胆固醇和体重指数(BMI)的个体内变异性定义为所有可用献血时间点的变异系数(CV)(范围为 3 至 74);参与者被分为 CV 四分位数。通过多变量二项式回归评估关联。
总体而言,3344 名参与者提供了 42090 份献血(中位数 9 [IQR 5, 17])。第一次研究献血时的中位年龄为 48 岁(38, 56)。由于 COVID-19 住院的比例为 1.2%(N=40),而患有 PCC 的比例为 15.5%(N=519)。BMI 变异性较高与 COVID-19 住院风险增加相关(第 4 四分位间距 aRR 4.15 [95% CI 1.31, 13.11],p=0.02;第 3 四分位间距 aRR 3.41 [95% CI 1.09, 10.69],p=0.04)。BMI 变异性较高的参与者发生 PCC 的风险更高(第 4 四分位间距 aRR 1.29 [95% CI 1.02, 1.64];p=0.04)。血压(收缩压、舒张压)和总循环胆固醇的个体内变异性与 COVID-19 住院或 PCC 风险无关(所有 p>0.05)。因果中介分析表明,BMI 变异性最高四分位数与 PCC 之间的关联不受住院的中介影响(p>0.05)。
BMI 的个体内变异性较高与 COVID-19 住院和 PCC 风险相关。我们的研究结果强调了进一步阐明解释这些关联的机制以及保持体重稳定的重要性的必要性。